Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Study of the Safety, Pharmacokinetic and Pharmacodynamic Properties of Intravenously Administered APG-1252 in Patients With Small Cell Lung Cancer (SCLC) or Advanced Solid Tumors.

Next Previous
Trial Profile

A Phase I Study of the Safety, Pharmacokinetic and Pharmacodynamic Properties of Intravenously Administered APG-1252 in Patients With Small Cell Lung Cancer (SCLC) or Advanced Solid Tumors.

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Nov 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs APG 1252 (Primary)
  • Indications Brain metastases; Small cell lung cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Ascentage Pharma

    • Most Recent Events

    • 13 Nov 2018 Pooled results from three phase I studies presented in an Ascentage Pharma media release.
    • 13 Nov 2018 According to an Ascentage Pharma media release, Professor Yi-Long Wu is the principal investigator of the trial.
    • 21 Feb 2018 According to an Ascentage Pharma media release, preliminary data from ongoing phase 1 trials of APG-1252 will be presented at International Association for the Study of Lung Cancer (IASLC) 18th Lung Cancer Targeted Therapies Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top